Balance is good...I am for balance. I took the test from
Balance is good...I am for balance. I took the test from the article and scored a 3 on the test. I am curious to know if you read the article and took the test to see your balance Craigakess? Or maybe lack of balance?
So for your benefit and so you don’t have to read the whole article. I have a link direct to the article test for you. If you chose to take the test. You can just PM me your results and you don’t have to post them for all to see. Don’t want to hurt your reputation of not being a optimist or anything. I am courious to see if you are a self defined optimist at heart or just trying to fool me...and maybe others. But if you PM me I won’t tell. It will be in confidence. Since we have had conversations like this before. It will help us both to clear the air.
file:///var/mobile/Library/SMS/Attachments/d5/05/E3FDEA3B-7A59-404C-87B2-BCD8CFAE1FBC/IMG_9724.jpegP
By the way, when it comes to protecting our investment in CYDY. I will go to bat for us all and myself to protect it from bashers and shorts and anyone who seems suspect in their motives.
Why would I do this? It’s because I believe completely in Leronlimab and feel all the bashing and short attacks have belittled this company and taken legitimacy away from a what should respected biotech based on the science alone. The management is just fine also. I am not a Nader Hater and hope he leads us to the promise land. To many doctors are on board with the science of this molecule for it not to have the utmost respect and I try to make sure that in my small insignificant way that it has that respect. It’s what I believe will help this drug overcome the doubt that others sew for all to read. Do I feel I need to protect our investment. Yes... I do!
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Frontera Energy Announces First Quarter Financial Results Frontera Energy Corporation (TSX: FEC) has exciting news for its shareholders and interested investors. The Company is set to unveil its financial and operational results for the first quarter, wrapping up on March 31, 2025. This significant announcement will occur after the market closes on a forthcoming Thursday...
Continue Reading
Exploring the Global Market for Contrast Media Injectors The global market for contrast media injectors is on the verge of substantial growth, with projections indicating it will reach $2.1 billion in the coming years. This anticipated growth, at a compound annual growth rate (CAGR) of 7.8% from 2025 through 2033, is primarily driven by ongoing advances in technology and...
Continue Reading
Beth Wozniak's Recent Stock Sale at nVent Electric Beth Wozniak, Chair & CEO of nVent Electric (NYSE:NVT), executed a significant insider sale recently, as revealed in a new SEC filing. This transaction involved the offloading of 7,597 shares, with a total value of approximately $884,822. Such movements in stock ownership often pique the interest of investors, prompting...
Continue Reading
The Impact of Home Prices on the Upcoming Election As we approach the presidential election, the role that home prices play in shaping voter sentiments is becoming increasingly evident. Recent research has shown that fluctuations in the housing market can significantly affect how voters make their choices, particularly in crucial battleground states. Current Trends in...
Continue Reading
Iambic Therapeutics Welcomes Michael Secora as CFO and CDO Iambic Therapeutics has announced an important leadership change, appointing Michael Secora, Ph.D., as its Chief Corporate Development Officer and Chief Financial Officer. This decision comes as Iambic continues its commitment to pioneering novel medicines through its innovative AI-driven drug discovery platform....
Continue Reading